Are pharmaceutical makers becoming outcomes companies? with AJ Ploszay, Ph.D. (GlaxoSmithKline) Brad Ansley (SPI Health)
Digital is disrupting pharmaceutical companies at their very core: product development and commercial operations. We explore this with two leaders deep in the thick of transforming this key healthcare segment . . . 10% of the overall healthcare spend in the US . . . as digital innovation destroys and recreates the industry.